
Reset all filters
01 2Alliance revenue - Lynparza
02 15Lynparza
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,776
2019 Revenue in Millions : 1,198
Growth (%) : 48
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 725
2019 Revenue in Millions : 444
Growth (%) : 63
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 2,348
2020 Revenue in Millions : 1,776
Growth (%) : 32
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 989
2020 Revenue in Millions : 725
Growth (%) : 36
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 1,116
2021 Revenue in Millions : 989
Growth (%) : 13
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 2,638
2021 Revenue in Millions : 2,348
Growth (%) : 12
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 2,811
2022 Revenue in Millions : 2,638
Growth (%) : 7
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,199
2022 Revenue in Millions : 1,116
Growth (%) : 7
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 3,072
2023 Revenue in Millions : 2,811
Growth (%) : 9
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 1,311
2023 Revenue in Millions : 1,199
Growth (%) : 9